B-Won Medison Makes 'Chemotherapy-Free' Gamble in Blood Cancer...Potential for Expanded Partnership with SillaJen

B-Won Medison's blood cancer treatment 'Brukinsa (zanubrutinib)' has attracted attention for securing successful chemotherapy-free data in the first-line treatment market for mantle cell lymphoma (MCL), meaning treatment without the use of chemotherapeutic agents.

According to the bio industry on July 14, B-Won Medison recently achieved results in a phase 3 clinical trial (MANGROVE) for first-line treatment of MCL, where the standard chemotherapeutic agent with a high toxic burden (bendamustine) was completely excluded while still improving progression-free survival (PFS) by 43% compared to the standard of care. This is being evaluated as a highly visible, proprietary chemotherapy-free clinical achievement, as it not only enhances patient safety and tolerability, but also boosts therapeutic efficacy.

As B-Won Medison strengthens its influence in the blood cancer sector by focusing on the chemotherapy-free strategy, there are projections that its strategic alliance with domestic partner SillaJen could also expand into the field of hematologic malignancies. SillaJen is currently conducting a global phase 1 clinical trial targeting solid tumors by combining its core pipeline, the mitotic checkpoint inhibitor 'BAL0891', with B-Won Medison's immune checkpoint inhibitor 'Tebumbra (tislelizumab)'. Given that the two companies have already established a solid joint front in solid tumor therapeutics, there is growing expectation for the partnership to extend into blood cancer in the future.

Image of Biwon Medicine research facility located in Hopewell, New Jersey, USA. Biwon Medicine

What stands out is that SillaJen is rapidly expanding its area beyond solid tumors into blood cancer through BAL0891. SillaJen has received approval for an amended investigational new drug (IND) application for patients with acute myeloid leukemia (AML) from both the U.S. Food and Drug Administration (FDA) and the Korean Ministry of Food and Drug Safety, and has begun global clinical development in earnest. BAL0891, which is under development as a first-in-class targeted therapy, has already shown strong synergistic effects in preclinical studies when used in combination with other blood cancer treatments, and meaningful tumor growth suppression and extended survival even as a monotherapy.

In addition, B-Won Medison is accelerating the expansion of its blood cancer pipeline by bringing next-generation agents such as the BCL2 inhibitor (sonrotoclax) and BTK degrader (BGB-16673) to the forefront, which is considered positive news for SillaJen. Given B-Won Medison's development direction—leading a generational shift and diversification in blood cancer therapeutics—BAL0891, which is proving its potential in the blood cancer field through an innovative mechanism (TTK/PLK1 dual inhibition), could become a complementary card targeting the global hematologic malignancy market.

An industry insider commented, "As B-Won Medison is pursuing multi-faceted expansion in the blood cancer market through its chemotherapy-free strategy, next-generation targeted agents with reduced toxicity concerns can serve as attractive combination options. Since BAL0891 is already part of a partnership for solid tumor clinical trials, there is a high likelihood that the scope of collaboration will be expanded to blood cancer indications in the future."

This content was produced with the assistance of AI translation services.